Zevra Therapeutics is expected to report Q3 2026 consensus revenue of $37.08 million and EPS of $0.14, while the current stock price of $10.33 sits significantly below the average analyst target of $25.25.
The primary focus for investors is the commercial sales trajectory of Miplyffa for Niemann-Pick disease type C following its successful U.S. launch and steady patient adoption. Analysts are specifically looking for continued growth in patient enrollment forms and expanded payer access, which previously reached 69% of covered lives.
Strong performance in these metrics is critical as the company also pursues a regulatory re-examination in the European market to further broaden its commercial footprint.